Jazz Pharmaceuticals acquires UK medical cannabis firm for $7.2bn
04-02-2021
Hikma enters settlement agreement with Jazz to sell Xyrem generic
07-04-2017
Kieferpix / iStockphoto.com
The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem (sodium oxybate).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Jazz Pharmaceuticals, US Court of Appeals for the Federal Circuit, generics, Xyrem, Amneal, inter partes reviews, IPRs, PTAB
